Breaking News

Catalent Ups Stake in Redwood Bioscience

April 3, 2014

Catalent Pharma Solutions has increased its minority investment in Redwood Bioscience. The decision was based on data generated by the SMARTag ADC platform, a precision protein-chemical engineering platform and novel toxin-linker technology developed by Redwood to enable the generation of homogeneous antibody-drug conjugates (ADCs) engineered to enhance potency, safety and stability. Employing Redwood’s SMARTag ADC platform combined with Catalent’s GPEx cell line expression system, the companies recently completed a biomanufacturing Center of Excellence in Madison, WI, offering a range of analytical and fill-finish services.  
In April of last year, Catalent had acquired an exclusive license to market the SMARTag technology and has since collaborated with Redwood for the development and marketing of the technology. As part of the collaboration, Catalent took a minority equity stake in Redwood, which may increase over time and could lead to a potential acquisition.  

“The potential that we initially identified in the SMARTag technology has been borne out by the successful achievement of in vivo and in vitro proof of concept milestones, leading to our next phase of investment,” said Barry Littlejohns, president, Advanced Delivery Technologies. He added “These studies have further illustrated that our ongoing collaboration with Redwood will offer significant and differentiating value to our growing number of customers looking to develop next-generation ADC therapies.”   

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important